Health Care • Biotechnology: Pharmaceutical Preparations
$22.01 ▲ +0.40
(+1.85%)
MKT CAP: $1.36B • VOL: 460.3K
52W L $5 52W H $38
ROARABLE / RQD
D • 47/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$18
MEDIAN
$25
MEAN
$25
HIGH
$30
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DMRA TAPE
DMRA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $26.63 | $25.31 | 2025-02-14 | $20.03 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $27.73 | $25.97 | 2025-02-06 | $20.69 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $25.09 | $24.21 | 2025-01-29 | $21.13 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $22.45 | — | 2025-01-17 | $21.57 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $19.37 | $20.91 | 2025-01-09 | $19.59 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $26.19 | $22.89 | 2024-12-18 | $19.15 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $21.35 | $22.23 | 2024-12-04 | $20.47 | -4.3% | 48% | C |